ContraFect Corp

22R

Company Profile

  • Business description

    ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

  • Contact

    28 Wells Avenue
    3rd Floor
    YonkersNY10701
    USA

    T: +1 914 207-2300

    E: [email protected]

    https://www.contrafect.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    23

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,462.6040.900.49%
CAC 407,743.7549.310.64%
DAX 4023,499.32146.630.63%
Dow JONES (US)41,249.38119.07-0.29%
FTSE 1008,554.8023.190.27%
HKSE22,867.7491.820.40%
NASDAQ17,928.920.780.00%
Nikkei 22537,503.33574.701.56%
NZX 50 Index12,605.07138.041.11%
S&P 5005,659.914.03-0.07%
S&P/ASX 2008,231.2039.500.48%
SSE Composite Index3,342.0010.00-0.30%

Market Movers